

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sueki R, <u>Enomoto N</u> , et al	Correlation between Pretreatment Viral Sequences and the Emergence of Lamivudine Resistance in Hepatitis B Virus Infection	Journal of Medical Virology			2012
Maekawa S, <u>Enomoto N</u> , et al	Comprehensive analysis for viral elements and il28b polymorphisms in response to peginterferon plus ribavirin therapy in hcv-1b infection	Hepatology			2012
Asahina Y, <u>Enomoto N</u> , et al.	Association of Gene Expression Involving Innate Immunity and Genetic Variation in Interleukin 28B With Antiviral Response	Hepatology	55	20-29	2012
Kurosaki M, <u>Enomoto N</u> , et al.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors	Hepatology	54	439-448	2011
Kurosaki M, <u>Enomoto N</u> , et al.	Genome-wide association study identified ITPA/DDR1G1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Human Molecular Genetics.	20	3507-3516	2011

Miura M, <u>Enomoto N</u> , et al.	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C	Hepatol Int.			2011
Kadokura M, <u>Enomoto N</u> , et al.	Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy	PLoS ONE	6	1-9	2011
Shindo H, <u>Enomoto N</u> , et al.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients	Hepatol Int			2011
Tanaka D, <u>Enomoto N</u> , et al.	A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors	Bioorganic & Medicinal Chemistry			2011
Wakita T, <u>Enomoto N</u> , et al.	Will There Be an HCV Meeting in 2020? Summary of the 17 <sup>th</sup> International Meeting on Hepatitis C Virus and Related Viruses	Gastroenterology	141		2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takaya D, Yamashita A, Kamijo K, Gomi J, Ito M, Maekawa S, Enomoto N, Sakamoto N, Watanabe Y, Arai R, Umeyama H, Honma T, Matsumoto T, Yokoyama S.	A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.	Bioorg Med Chem.	19	6892-6905	2011

## 別紙 4

## 研究成果の刊行に関する一覧表レイアウト (参考)

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takaya D, Yamashita A, Kamijo K, Gomi J, Ito M, Maekawa S, Enomoto N, Sakamoto N, Watanabe Y, Arai R, Umeyama H, Honma T, Matsumoto T, Yokoyama S.	A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.	<i>Bioorganic &amp; Medicinal Chemistry</i>	19	6892-6905	2011

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Yasuhiro Asahina</u> , Kaoru Tsuchiya, Masaru Murooka, Keisuke Tanaka, Yuichiro Suzuki, Nobuharu Tamaki, Yoshihide Hoshiooka, Yutaka Yasui, Tomoji Katoh, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Sayuri Nitta, Naoya Sakamoto, Namiki Izumi.	Association of gene expression involving innate immunity and genetic variation in <i>IL28B</i> with antiviral response	Hepatology	2012;55	20-29	2011
Masayuki Kurosaki, <u>Yasuhiro Asahina</u> , Namiki Izumi, et., al.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in <i>IL28B</i> and viral factors	Journal of Hepatology	54	439-448	2011
<u>Yasuhiro Asahina</u> , Namiki Izumi, et., al.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients	Hepatology International	On line		2011

Kaoru Tsuchiya, Mina Komuta, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Teiji Kuzuya, Jun Itakura, Hiroyuki Nakanishi, Yuka Takahashi, Masayuki Kurosaki, <u>Yasuihiro Asahina</u> , Nobuyuki Enomoto, Michiie Sakamoto, Namiki Izumi ..	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation	Oncology		278-288	2011
Teiji Kuzuya, <u>Yasuhiro Asahina</u> , Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda,, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Namiki Izumi ..	Early Decrease in $\alpha$ -Fetoprotein, but Not Des- $\gamma$ -Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma	Oncology	81	251-258	2011
Itakura J, <u>Asahina Y</u> , Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider, Izumi N.	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.	Heptol Res	In press		2011
朝比奈靖浩	C型肝炎抗ウイルス治療と自然免疫系	臨床消化器内科	Vol.26(11)	545-552	2011
朝比奈靖浩	MK7009	肝胆膵	Vol.62(2)	385-388	2011
朝比奈靖浩、泉並木	C型肝炎治療のpitfall	Medical Practice	Vol.28(8)	1430-1434	2011
朝比奈靖浩.	ウイルス肝炎 治療の現状と新しい戦略】 C型肝炎ウイルス感染の病態と治療法 ペグインターフェロンとリバビリン併用療法の治療成績と寄与因子.	治療学	44	1016-1021,	2011

## 研究成果の刊行に関する一覧表

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hiraga N, Abe H, <u>Imamura M</u> , Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K	Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	54(3)	764-71	2011
Hiraga N, <u>Imamura M</u> , Abe H, Nelson Hayes C, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.	Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo.	Hepatology	54(3)	781-88	2011

## 研究成果の刊行に関する一覧表

## 書籍

者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
-----	---------	---------------	-------	------	-----	-----	-----

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Nakamoto Y</u> , Mizukoshi E, Kitahara M, Arihara F, Sakai Y, Kakinoki K, Fujita Y, Marukawa Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S	Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.	Clin. Exp. Immunol.	163(2)	165-177	2011
Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, <u>Nakamoto Y</u> , Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.	Gastroenterology	141(1)	128-140	2011
Takata Y, <u>Nakamoto Y</u> , Nakada A, Terashima T, Arihara F, Kitahara M, Kakinoki K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S	Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma.	Cancer Lett.	307(2)	165-173	2011

## 研究成果の刊行に関する一覧表（堀田 博）

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, <u>Hotta H</u>	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon /ribavirin therapy.	PLoS ONE	7(2)	e30513	2012
El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, <u>Hotta H</u>	Polymorphisms of hepatitis C virus NS5A and core proteins and clinical outcome of pegylated Interferon/Ribavirin combination therapy.	Intervirology	55(1)	1-11	2012
Sasayama M, Shoji I, Adianti M, Jiang D-P, Deng L, Saito T, Watanabe H, Kawata S, Aoki C, <u>Hotta H</u>	A point mutation at ASN-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis c virus markedly enhances the sensitivity to antibody neutralization.	J Med Virol	84(2)	229-234	2012
Shoji I, Deng L, <u>Hotta H</u>	Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders.	Front Microbiol	2: A278	1-5	2012

Kamada K, Shoji I, Deng L, Aoki C, Ratnoglik SL, Wakita T, <u>Hotta H</u>	Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production.	Microbes Infect	14(1)	69-78	2012
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, <u>Hotta H</u> , Maekawa Y, Hayashi Y, Kudo M	Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.	Digestion	84 Suppl 1	5-9	2011
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, <u>Hotta H</u> , Kudo M	Double-filtration plasmapheresis plus interferon- $\beta$ for HCV-1b patients with non-sustained virological response to previous combination therapy.	Digestion	84 Suppl 1	10-16	2011
Nakashima K, Takeuchi K, Chihara K, <u>Hotta H</u> , Sada K	Inhibition of hepatitis C virus replication through AMP-activated protein kinase-dependent and -independent pathways.	Microbiol Immunol,	55(11)	774-782	2011

Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP, Ide YH, <u>Hotta H</u>	Hepatitis C virus infection promotes Hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.	J Virol	85(17)	8556-8568	2011
El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, <u>Hotta H</u>	Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon /ribavirin combination therapy.	Microbiol Immunol	55(6)	418-426	2011
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	NS5A-IRRDR変異数 .	医学のあゆみ	239 (12-13)	1208-1211	2011
勝二郁夫, El-ShamyAhmed, <u>堀田博</u>	C型肝炎ウイルス NS5A領域のISDR・IRRDRとインターフェロン治療効果予測.	肝胆膵	63(6)	1063-1069	2011

## 研究成果の刊行に関する一覧表

書籍  
無し

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, Kato T, Matsuura Y, Watanabe H, Wakita T, <u>Suzuki T.</u>	Role of the ERAD pathway in degradation of hepatitis C virus envelope proteins and production of the viral particles.	J Biol Chem	286	37264-37273	2011
Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, <u>Suzuki T.</u>	Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen Virol	92	2082-2087	2011
Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, <u>Suzuki T</u> , Wakita T	Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.	Vaccine	29	4821-4828	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, <u>Suzuki T</u> , Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, Wakita T, Kato T.	In Vivo adaptation of hepatitis C virus for efficient virus production and evasion of apoptosis.	Hepatology	54	425-433	2011
Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M,	Malnutrition Impairs Interferon Signaling Through mTOR and FoxO Pathways in Patients With Chronic Hepatitis C.	Gastroenterology	141	128-140	2011

Shimakami T, Yi M, Lemon SM, <u>Suzuki T</u> , Wakita T, Kaneko S. T.					
Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, <u>Suzuki T</u> , Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K.	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein.	J Hepatol.	54	432-438	2011
Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, <u>Suzuki T</u> , Tatsumi M, Moriishi K, Matsuura Y.	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One.	6	E15967	2011
Watanabe N, Aizaki H, Matsuura T, Kojima S, Wakita T, <u>Suzuki T</u> .	Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules.	Biochem Biophys Res Commun.	407	135-140	2011
Inoue Y, Aizaki H, Hara H, Matsuda M, Ando T, Shimoji T, Masaki T, Shoji I, Homma S, Matsuura Y, Miyamura T, Wakita T, <u>Suzuki T</u> .	Chaperonin TRiC/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein.	Virology	410	38-47	2011

## 研究成果の刊行に関する一覧表レイアウト (参考)

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Suzuki F</u> , Suzuki Y, Akuta N, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Kamatani N, Nakamura Y, Chayama K, Kumada H.	Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.	Hepatology	53(2)	415-21	2011
C Nelson H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H, Abe H, Miki D, Imamura M, Ochi H, Katanamik N, Nakamura Y, Chayama K.	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Gut	60	261-7	2011
Chayama K, C Nelson H, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H.	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.	J Infect Dis	204	84-93	2011
Arase Y, Suzuki Y, <u>Suzuki F</u> , Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M,	Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.	Interna Medicine	50	1-7	2011

Kumada H.					
Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Saitoh S, Arase Y, Kumada H.	Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.	Hepatol Res.	41(11)	1036-45	2011
Arase Y, <u>Suzuki F</u> , Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, Sezaki H, Hosaka T, Ogawa K, Imai N, Seko Y, Saito S, Ikeda K, Kobayashi M, Kumada H.	Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.	Hepatol Res.	41(10)	946-54	2011
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.	Oncology	80(3-4)	188-94	2011
Arase Y, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T.	The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.	Intern Med.	50(10)	1081-7	2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M,	Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis	J Med Virol	83(6)	1016-22	2011

Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	following eradication of HCV RNA by antiviral therapy.				
Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.	Liver Int.	31(5)	692-9	2011
Arase Y, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kobayashi T.	Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.	Hepatol Res.	41(6)	524-9	2011
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, <u>Suzuki F</u> , Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.	J Med Virol	83(6)	1048-57	2011
Yamada I, <u>Suzuki F</u> , Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, Kumada H.	Safety, pharmacokinetics, and resistant variants of telaprevir for 12 weeks in hepatitis C virus genotype 1b infection.	J Viral Hepat Jul	Epub ahead of print		2012
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.	Intervirolgy	Epub ahead of print		2011
Akuta N, <u>Suzuki F</u> , Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M,	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics	Intervirolgy	Epub ahead of print		2011

Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	during telaprevir, peginterferon and ribavirin treatment.				
Imai N, Ikeda K, Seko Y, Matsumoto N, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki E, Suzuki Y, Arase Y, Kumada H.	Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure.	Nihon Shokakibyō Gakkai Zasshi	108(11)	1872-8	2011
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki E, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H.	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma.	Am J Gastroenterol	Epub ahead of print		2011
鈴木義之、瀬崎ひとみ、芥田憲夫、鈴木文孝、今井則博、平川美晴、川村祐介、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	NS5A 阻害剤と NS3 プロテアーゼ阻害剤併用投与における早期抗ウイルス効果	肝臓	52(2)	147-9	2011
保坂哲也、鈴木文孝、小林正宏、瀬古裕也、今井則博、平川美晴、川村祐介、瀬崎ひとみ、芥田憲夫、鈴木義之、斎藤聡、荒瀬康司、池田健次、小林万利子、熊田博光	B 型慢性肝疾患に対する核酸アナログ療法による HBs 抗原消失とその関連因子の検討	肝臓	52(4)	255-7	2011
小林万利子、鈴木文孝、鈴木義之、芥田憲夫、瀬崎ひとみ、川村祐介、瀬古裕也、保坂哲也、小林正宏、斎藤聡、荒瀬康司、池田健次、熊田博光	コバス TaqManHBV「オート」v2.0 における同一時の血清検体と血漿検体の HBVDNA 検出率の検討	肝臓	52(11)	756-7	2011

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
	Q5. HBc抗体・HBs抗体のみが陽性の患者はどのような点に注意して診療すべきか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	24-27
	Q13. B型肝炎の症例にも、インターフェロンや核酸アナログの治療適応はあるか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	51-53

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ueyama M, <u>Nakagawa M</u> (equal contribution), et al.	Serum interleukin-6 levels can predict resistance to treatment of chronic hepatitis C infection with pegylated-interferon alpha 2b plus ribavirin.	<i>Antiviral Therapy</i>	16	1081-1091	2011
Sakamoto N, <u>Nakagawa M</u> (equal contribution), et al.	Association of IL28B polymorphism with response to pegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C.	<i>J Medical Virol</i>	83	871-878	2011
Funaoka Y <u>Nakagawa M</u> , et al.	Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.	<i>J Virol</i>	85	5986-94	2011
Kurosaki M <u>Nakagawa M</u> , et al.	Pretreatment Prediction of Response to Pegylated-Interferon Plus Ribavirin for Chronic Hepatitis C using Genetic Polymorphism in IL28B and Viral Factors.	<i>J Hepatol</i>	54	439-48	2011
Watanabe T <u>Nakagawa M</u> , et al.	Inhibitory effect of triterpenoid compound with or without interferon-alpha on Hepatitis C virus infection.	<i>Antimicrob Agent Chemother</i>	55	2537-45.	2011

Onozuka I, <u>Nakagawa M</u> , et al.	Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice.	<i>Biochem Biophys Res Commun</i>	406	134-140	2011
Yamamoto M, <u>Nakagawa M</u> , et al.	Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture.	<i>Hepatology Res</i>	41	258-69	2011
<u>Nakagawa M</u> , Sakamoto N (equal contribution)	Mutations in the Interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.	<i>J Gastroenterology</i>	45	656-65	2010
Kurosaki M <u>Nakagawa M</u> , et al.	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis	<i>J Medical Virol</i>	83	445-52	2011
Karakama Y <u>Nakagawa M</u> , et al.	Inhibition of HCV replication by a specific inhibitor of serine-arginine-rich protein kinase.	<i>Antimicrobial Agents and Chemotherapy</i>	54	3179-3186	2010
Suda G <u>Nakagawa M</u> , et al.	IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.	<i>Virology</i>	407	80-90	2010
Sakamoto N <u>Nakagawa M</u> , et al.	ITPA gene variant protects against anemia induced by pegylated interferon-a and ribavirin therapy for Japanese patients with chronic hepatitis C.	<i>Hepatology Res</i>	40	1063-1071	2010
中川美奈、坂本直哉、渡辺守	Cyclophilin inhibitors	肝胆膵	62巻2号	403-411	2011
植山真由美、中川美奈、坂本直哉、渡辺守	ホルモン・サイトカインから見た肝発癌機構の性差 IL-6と肝炎・肝発癌	肝胆膵	60巻5号	849-856	2010

研究成果の刊行に関する一覧表レイアウト

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kumar V, Kato N, et al.	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.	Nat Genet	43	455-458	2011
加藤直也, 他	GWAS による C 型肝炎感 受性遺伝子の同定	肝胆膵	62 巻 5 号	919-925	2011
加藤直也.	肝発癌の分子機構	The Liver Cancer Journal	3 巻	15-25	2011
加藤直也, 他	C 型肝炎の GWAS 研究 : MICA SNP	肝胆膵	62 巻 12 号	1045-1051	2011
加藤直也, 他	新規薬剤(新規プロテア ーゼ阻害薬, IFN $\alpha$ など )	医学のあゆみ	239 巻	1175-1181	2011